Difference between revisions of "Afamitresgene Autoleucel (ADP-A2M4)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/afamitresgene-autoleucel NCI Drug Dictionary]: A preparation of autologous h...") |
m (→Liposarcoma) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Liposarcoma]]=== | ===[[Liposarcoma]]=== | ||
| − | #'''SPEARHEAD-1:''' D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 | + | #'''SPEARHEAD-1:''' D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 Apr 13;403(10435):1460-1471. Epub 2024 Mar 27. [https://doi.org/10.1016/s0140-6736(24)00319-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/38554725/ PubMed] [https://clinicaltrials.gov/study/NCT04044768 NCT04044768] |
==Also known as== | ==Also known as== | ||
| Line 11: | Line 11: | ||
[[Category:Anti-MAGE-A4 SPEAR T-cells]] | [[Category:Anti-MAGE-A4 SPEAR T-cells]] | ||
| − | |||
[[Category:Liposarcoma medications (investigational)]] | [[Category:Liposarcoma medications (investigational)]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Latest revision as of 21:42, 21 June 2024
Mechanism of action
From the NCI Drug Dictionary: A preparation of autologous human T-lymphocytes transduced with a lentiviral vector encoding an affinity-enhanced T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A2-restricted peptide human melanoma antigen A4 (MAGE-A4) C1032, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, afamitresgene autoleucel targets and binds to tumor cells expressing MAGE-A4. This results in cell death of MAGE-A4-expressing tumor cells.
Preliminary data
Liposarcoma
- SPEARHEAD-1: D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 Apr 13;403(10435):1460-1471. Epub 2024 Mar 27. link to original article PubMed NCT04044768
Also known as
- Code name: ADP-A2M4
- Generic name: afami-cel